INTRODUCTION: Distraction osteogenesis (DO) is characterized by the induction of highly vascularized new bone formation through an intramembranous process largely devoid of the formation of cartilage. MATERIALS AND METHODS: To test the hypothesis that DO is strictly dependent on vascualrization, we inhibited vascular endothelial growth factor (VEGF) activity by antibody blockade of both receptors VEGFR1 (Flt-1) and VEGFR2 (Flk-1) or only VEGFR2 (Flk-1) in a previously developed murine tibia DO model. During normal DO, VEGFR1 (Flt-1), VEGFR2 (Flk-1), VEGFR3 (Flt4) and all four VEGF ligand (A, B, C, and D) mRNAs are induced. RESULTS: The expression of mRNA for the receptors generally paralleled those of the ligands during the period of active distraction. Bone formation, as assessed by muCT, showed a significant decrease with the double antibody treatment and a smaller decrease with single antibody treatment. Vessel volume, number, and connectivity showed progressive and significant inhibition in all of these of parameters between the single and double antibody blockade. Molecular analysis showed significant inhibition in skeletal cell development with the single and double antibody blockade of both VEGFR1 and 2. Interestingly, the single antibody treatment led to selective early development of chondrogenesis, whereas the double antibody treatment led to a failure of both osteogenesis and chondrogenesis. CONCLUSIONS: Both VEGFR1 and VEGFR2 are functionally essential in blood vessel and bone formation during DO and are needed to promote osteogenic over chondrogenic lineage progression.
INTRODUCTION: Distraction osteogenesis (DO) is characterized by the induction of highly vascularized new bone formation through an intramembranous process largely devoid of the formation of cartilage. MATERIALS AND METHODS: To test the hypothesis that DO is strictly dependent on vascualrization, we inhibited vascular endothelial growth factor (VEGF) activity by antibody blockade of both receptors VEGFR1 (Flt-1) and VEGFR2 (Flk-1) or only VEGFR2 (Flk-1) in a previously developed murine tibia DO model. During normal DO, VEGFR1 (Flt-1), VEGFR2 (Flk-1), VEGFR3 (Flt4) and all four VEGF ligand (A, B, C, and D) mRNAs are induced. RESULTS: The expression of mRNA for the receptors generally paralleled those of the ligands during the period of active distraction. Bone formation, as assessed by muCT, showed a significant decrease with the double antibody treatment and a smaller decrease with single antibody treatment. Vessel volume, number, and connectivity showed progressive and significant inhibition in all of these of parameters between the single and double antibody blockade. Molecular analysis showed significant inhibition in skeletal cell development with the single and double antibody blockade of both VEGFR1 and 2. Interestingly, the single antibody treatment led to selective early development of chondrogenesis, whereas the double antibody treatment led to a failure of both osteogenesis and chondrogenesis. CONCLUSIONS: Both VEGFR1 and VEGFR2 are functionally essential in blood vessel and bone formation during DO and are needed to promote osteogenic over chondrogenic lineage progression.
Authors: M Prewett; J Huber; Y Li; A Santiago; W O'Connor; K King; J Overholser; A Hooper; B Pytowski; L Witte; P Bohlen; D J Hicklin Journal: Cancer Res Date: 1999-10-15 Impact factor: 12.701
Authors: Hairong Peng; Arvydas Usas; Anne Olshanski; Andrew M Ho; Brian Gearhart; Gregory M Cooper; Johnny Huard Journal: J Bone Miner Res Date: 2005-07-18 Impact factor: 6.741
Authors: Kevin Wang; Prashanth Vishwanath; Gabriel S Eichler; Maisa O Al-Sebaei; Cory M Edgar; Thomas A Einhorn; Temple F Smith; Louis C Gerstenfeld Journal: Matrix Biol Date: 2006-03-06 Impact factor: 11.583
Authors: Mitchell S Fourman; Eugene W Borst; Eric Bogner; S Robert Rozbruch; Austin T Fragomen Journal: Clin Orthop Relat Res Date: 2013-08-29 Impact factor: 4.176
Authors: Wuchen Yang; Dayong Guo; Marie A Harris; Yong Cui; Jelica Gluhak-Heinrich; Junjie Wu; Xiao-Dong Chen; Charles Skinner; Jeffry S Nyman; James R Edwards; Gregory R Mundy; Alex Lichtler; Barbara E Kream; David W Rowe; Ivo Kalajzic; Val David; Darryl L Quarles; Demetri Villareal; Greg Scott; Manas Ray; S Liu; James F Martin; Yuji Mishina; Stephen E Harris Journal: J Cell Sci Date: 2013-07-10 Impact factor: 5.285
Authors: Mattias K Andersson; Melker Göransson; Anita Olofsson; Carola Andersson; Pierre Aman Journal: BMC Cancer Date: 2010-06-01 Impact factor: 4.430